GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
about
G protein-coupled receptors as new therapeutic targets for type 2 diabetes.Investigational insulin secretagogues for type 2 diabetes.Implications for drug characterization in glucose tolerance tests without insulin: Simulation study of power and predictions using model-based analysis.Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines.Gut Hormone Regulation and Secretion via FFA1 and FFA4.Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose SelectionDesign, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists.Chewing the fat for better insulin secretion.A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.Free fatty acid receptor 1 agonist, MR1704, lowers blood glucose levels in rats unresponsive to the sulfonylurea, glibenclamide.Trends in GPCR drug discovery: new agents, targets and indications.Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).The current state of GPCR-based drug discovery to treat metabolic disease.β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation.Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 with in Vivo Activity in Rodents.Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.Ligands at Free Fatty Acid Receptor 1 (GPR40).Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein-Coupled Receptor 120.Optical control of GPR40 signalling in pancreatic β-cells.A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
P2860
Q38667727-11DFD949-6A98-4DF6-8D11-FF9D82C6DF6DQ38735419-7523DD9F-A3B2-4147-9F6A-E9891CE5607CQ38748188-B924EF11-CC92-4812-AF4A-3A5F6CC1A19FQ38792265-5E5DDC8C-3035-4E67-9FAB-A03D80DB0F5FQ38855180-0206812B-656E-4788-BC42-774DCEE54384Q38866310-4404A3A1-491F-48D7-B593-3CC72592FACCQ39016250-34C4D88D-8CC9-4CFD-BAFD-A50D601F16A0Q39016255-A724439A-312B-4499-B7BA-F4B0B4C67247Q41369032-C9C7374E-2447-45F8-A362-04BDD618624CQ42056687-AD5E5899-FB8C-4AB8-9944-07A4CB8E20D5Q43102249-4F25186F-ABC2-42E5-A884-C74BF81CD70FQ47123031-412E88AF-0DC8-445B-8210-664F370C726DQ47591876-C3C02D35-E2D4-483B-8A8E-24AA4A0A672CQ47597808-362D5C9F-4058-400A-9C4F-1A460C48FC0EQ47606086-735685D1-01E6-4AF3-8027-0E3257A9F655Q47696468-62EF4010-585E-4223-A313-E2617BF27E3EQ47843111-B047D847-56B8-41A0-BC37-BF3CE69BBEF0Q48170686-E67F53C8-D541-441E-9ADC-9373A89B2839Q48192313-9D248EDF-7465-4A21-B0A9-A311CDC02F6AQ51180153-2204FAD9-ED38-4930-A6A4-66BABEE82831Q51363044-F550DC89-B2D3-453C-96B3-4852ABBE8701Q51377008-0C77CAD4-1C3E-4A21-A565-39F0C7D5DBDEQ51739139-0AB91552-04BE-4DFB-8D35-DB75E9DF8859Q52345406-51A5C9EA-DD47-4099-9206-ED1CDF45023CQ52590826-CF29FBF8-C48C-44BA-A27F-DE6EA001514E
P2860
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
@en
type
label
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
@en
prefLabel
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
@en
P2860
P356
P1476
GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
@en
P2093
A D Mancini
P2860
P304
P356
10.1111/DOM.12442
P577
2015-02-24T00:00:00Z